Pharming Group Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Pharming Group de 42.5% y 14.6% respectivamente, mientras que el BPA crecerá en un 45% al año.

Información clave

42.5%

Tasa de crecimiento de los beneficios

45.02%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.9%
Tasa de crecimiento de los ingresos	14.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	04 Sep 2026

Actualizaciones recientes sobre el crecimiento futuro

Artículo de análisis • Aug 02

Earnings Report: Pharming Group N.V. Missed Revenue Estimates By 11%

One of the biggest stories of last week was how Pharming Group N.V. ( AMS:PHARM ) shares plunged 20% in the week since...

Recent updates

Artículo de análisis • Aug 02

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Pharming Group N.V. ( AMS:PHARM ) shareholders have had their patience rewarded with a 26% share price jump in the last...

Artículo de análisis • May 10

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

Pharming Group N.V. ( AMS:PHARM ) shares have had a really impressive month, gaining 29% after a shaky period...

Artículo de análisis • Dec 21

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

The Pharming Group N.V. ( AMS:PHARM ) share price has done very well over the last month, posting an excellent gain of...

Artículo de análisis • Feb 14

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at...

Artículo de análisis • Nov 11

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Artículo de análisis • Aug 23

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Pharming Group is €2.29 based on 2 Stage Free Cash Flow to Equity Current...

Artículo de análisis • Jun 20

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Previsiones de crecimiento de beneficios e ingresos

ENXTAM:PHARM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2028	430	32	92	N/A	2
12/31/2027	426	39	49	43	4
12/31/2026	383	25	-9	1	3
6/30/2026	366	9	34	35	N/A
3/31/2026	369	12	56	56	N/A
12/31/2025	376	3	54	55	N/A
9/30/2025	362	0	53	53	N/A
6/30/2025	340	-8	30	31	N/A
3/31/2025	321	-14	5	6	N/A
12/31/2024	297	-12	-3	-2	N/A
9/30/2024	286	-18	0	0	N/A
6/30/2024	278	-13	-6	-6	N/A
3/31/2024	258	-11	18	-2	N/A
12/31/2023	245	-11	3	-17	N/A
9/30/2023	219	-22	-4	-24	N/A
6/30/2023	206	-16	5	-15	N/A
3/31/2023	202	-2	-3	-1	N/A
12/31/2022	206	14	20	22	N/A
9/30/2022	204	30	25	33	N/A
6/30/2022	202	21	15	26	N/A
3/31/2022	202	11	17	31	N/A
12/31/2021	199	16	21	38	N/A
9/30/2021	200	22	29	43	N/A
6/30/2021	200	31	40	52	N/A
3/31/2021	202	37	59	70	N/A
12/31/2020	212	38	68	84	N/A
9/30/2020	212	44	70	85	N/A
6/30/2020	202	46	59	93	N/A
3/31/2020	202	42	N/A	84	N/A
1/1/2020	189	41	N/A	74	N/A
9/30/2019	175	38	N/A	70	N/A
6/30/2019	175	34	N/A	63	N/A
3/31/2019	158	29	N/A	57	N/A
12/31/2018	155	29	N/A	46	N/A
9/30/2018	152	-29	N/A	63	N/A
6/30/2018	138	-44	N/A	61	N/A
3/31/2018	128	-80	N/A	52	N/A
12/31/2017	108	-91	N/A	46	N/A
9/30/2017	76	-53	N/A	14	N/A
6/30/2017	47	-47	N/A	-6	N/A
3/31/2017	31	-21	N/A	-13	N/A
12/31/2016	17	-18	N/A	-11	N/A
9/30/2016	12	-16	N/A	-18	N/A
6/30/2016	12	-15	N/A	-18	N/A
3/31/2016	13	-14	N/A	-18	N/A
12/31/2015	12	-11	N/A	-19	N/A
9/30/2015	29	8	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (42.5% al año) de PHARM es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (42.5% al año) de PHARM crezcan más rápidamente que el mercado Dutch (17.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de PHARM crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14.6% al año) de PHARM crezcan más rápidamente que los del mercado Dutch (10.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14.6% al año) de PHARM crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PHARM se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/13 21:03
Precio de las acciones al final del día	2026/09/11 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Pharming Group N.V. está cubierta por 11 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Whitney Ijem	Canaccord Genuity
John Savin	Edison Investment Research
Simon Scholes	First Berlin Equity Research GmbH

Pharming Group Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Earnings Report: Pharming Group N.V. Missed Revenue Estimates By 11%

Pharming Group N.V. Revises Earnings Guidance for the Year 2026

Pharming Group N.V. Provides Earnings Guidance for the Financial Year 2026

Consensus forecasts updated

Price target increased by 7.4% to €2.19

Pharming Group N.V. Revises Revenue Guidance for Full Year 2025

Recent updates

FDA Approves Joenja as First Treatment for Pediatric APDS in the US

Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S

Pharming Group Launches Joenja in Japan for APDS Patients Aged 4 and Older

Pharming Group Announces Commercial Launch of Joenja in Japan for Adult and Pediatric Patients with Apds Aged 4 and Older

Earnings Report: Pharming Group N.V. Missed Revenue Estimates By 11%

Pharming Group N.V. Revises Earnings Guidance for the Year 2026

Second quarter 2026 earnings released: EPS: US$0.002 (vs US$0.007 in 2Q 2025)

PHARM: Pediatric APDS Approval And EU Launch Plans Will Drive Rerating

PHARM: Expanded Rare Disease Approvals Will Drive Future Upside Potential

Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja (Leniolisib) to Treat Children Aged 4 to 11 Years with APDS

Investor sentiment deteriorates as stock falls 18%

First quarter 2026 earnings released: US$0.007 loss per share (vs US$0.022 loss in 1Q 2025)

Pharming Group N.V. Receives Positive CHMP Opinion for Joenja® (Leniolisib) for the Treatment of APDS in Adult and Pediatric Patients 12 Years and Older

Pharming Group N.V. Announces Approval of Joenja for Treatment of APDS in Japan

Pharming Group N.V., Annual General Meeting, May 28, 2026

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Pharming Group N.V. to Report Q1, 2026 Results on May 07, 2026

Now 20% undervalued after recent price drop

Pharming Group N.V. Provides Earnings Guidance for the Financial Year 2026

Pharming Group Receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in Children Aged 4 to 11 Years with APDS

Consensus forecasts updated

Price target increased by 7.4% to €2.19

Pharming Group N.V. to Report Q4, 2025 Results on Mar 12, 2026

Pharming Group N.V. Revises Revenue Guidance for Full Year 2025

Pharming Group N.V. Announces Presentations at 2025 ACAAI Annual Scientific Meeting

Pharming Group N.V. Announces 20% Net Reduction in Non-Commercial and Non-Medical Headcount, Primarily at its Netherlands Headquarters

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Pharming Group N.V. Appoints Kenneth Lynard as Chief Financial Officer, Effective October 1, 2025

Price target increased by 7.2% to €2.04

Price target increased by 13% to €2.01

Second quarter 2025 earnings released: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)

New major risk - Share price stability

Pharming Group N.V. Revises Revenue Guidance for Full Year 2025

Pharming Group to Host Webcast on Findings of A New Study Published in Cell Advancing Functional Classification of Variants of Uncertain Significance (Vus) to Improve APDS Diagnosis

Pharming Group N.V. Approves Board Changes

New major risk - Share price stability

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

First quarter 2025 earnings released: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

Mr. Jeroen Wakkerman to Leave as Chief Financial Officer of Pharming Group N.V. on May 31, 2025

Pharming Group N.V. Receives Positive Recommendation from NICE for Joenja (Leniolisib) as a Treatment for APDS

Consensus EPS estimates upgraded to US$0.015 loss

Price target increased by 14% to €1.94

Pharming Group N.V. Announces First Patient Dosed in Phase II Clinical Trial of Leniolisib for Common Variable Immunodeficiency (CVID) with Immune Dysregulation

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Pharming Group N.V. to Report Q2, 2025 Results on Jul 31, 2025

Pharming Group N.V. Announces CEO Changes

Pharming Group N.V. Announces Board Changes

Pharming Group N.V. to Report Q4, 2024 Results on Mar 13, 2025

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Price target increased by 8.1% to €1.84

Pharming Group N.V. Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib

New major risk - Share price stability

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price